Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
Stewart J Tepper, Messoud Ashina, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Hernan Picard, Sunfa Cheng, Denise E Chou, Feng Zhang, Jan Klatt, Daniel D Mikol, Stewart J Tepper, Messoud Ashina, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Hernan Picard, Sunfa Cheng, Denise E Chou, Feng Zhang, Jan Klatt, Daniel D Mikol
Abstract
Background: In patients with migraine, overuse of acute medication, including migraine-specific medication (MSM) such as triptans and ergots, can lead to adverse health outcomes, including development of medication overuse headache. Here, we examined the effect of erenumab on reducing acute medication use, in particular MSM, in patients with episodic migraine (EM) and chronic migraine (CM).
Methods: The current post-hoc analyses were based on data from the double-blind treatment phase (DBTP) of two erenumab studies, a pivotal EM (N = 955) and a pivotal CM (N = 667) trial, and their respective extensions. Patients were administered subcutaneous placebo or erenumab (70 or 140 mg) once monthly. Daily acute headache medication use (including MSM and non-MSM) was recorded using an electronic diary during a 4-week pretreatment baseline period until the end of the treatment period. Outcome measures included change in monthly acute headache medication days (HMD) in acute headache medication users at baseline, and changes in monthly MSM days (MSMD) in MSM users at baseline and non-MSMD in non-MSM users at baseline.
Results: In total, 60 and 78 % of patients (all acute headache medication users) with EM and CM used MSM at baseline, respectively. For acute headache medication users, the change in mean monthly acute HMD over Months 4, 5 and 6 compared with the pre-DBTP was 1.5, 2.5, and 3.0 for placebo, erenumab 70 mg and 140 mg, respectively for the EM study. The respective change in monthly MSMD in MSM users was 0.5, 2.1 and 2.8, and in monthly non-MSMD in non-MSM users was 2.3, 2.6, and 2.7. In the acute headache medication users at baseline, the change in monthly acute HMD at Month 3 compared with pre-DBTP was 3.4, 5.5, and 6.5 for placebo, erenumab 70 mg and 140 mg, respectively for the CM study. The respective change in monthly MSMD in MSM users was 2.1, 4.5, and 5.4, and in monthly non-MSMD in non-MSM users was 5.9, 6.4, and 6.6. Reductions in MSMD versus placebo were sustained in the extension periods of both studies. Erenumab was also associated with a higher proportion of MSM users achieving ≥ 50 %, ≥ 75 and 100 % reduction from baseline in monthly MSMD versus placebo in both EM and CM.
Conclusions: In both EM and CM, treatment with erenumab is associated with a significant and sustained reduction in the use of acute headache medication, in particular MSM.
Trial registrations: NCT02456740; NCT02066415; NCT02174861.
Keywords: CGRP receptor; Chronic migraine; Episodic migraine; Erenumab; Migraine-specific.
Conflict of interest statement
SJT was an employee of the Cleveland Clinic during this study. He reports research grants (no personal compensation) from Allergan, Amgen Inc., ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; consultant fees from Acorda, Aeon, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, CRG, Currax, Decision Resources, DeepBench, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Healthcare Consultancy Group, Health Science Communications, Impel, Lundbeck, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pulmatrix, Reckner Healthcare, Relevale, Revance, SAI MedPartners, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, Zosano; advisory boards: Acorda, Aeon, Alder, Allergan, Amgen, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Biohaven, Charleston Laboratories, Currax, Eli Lilly, GSK, Impel, Lundbeck, Novartis, Satsuma, Theranica, Teva, XOC, Zosano; stock options from Nocira, Percept; salary from American Headache Society and Dartmouth-Hitchcock Medical Center; CME honoraria: American Academy of Neurology, American Headache Society, Cleveland Clinic Foundation, Diamond Headache Clinic, Elsevier, Forefront Collaborative, Hamilton General Hospital, Ontario, Canada, Headache Cooperative of New England, Henry Ford Hospital, Detroit, Inova, Medical Learning Institute Peerview, Medical Education Speakers Network, Miller Medical Communications, North American Center for CME, Physicians’ Education Resource, Rockpointe, ScientiaCME, WebMD/Medscape.
MA reports personal fees from Alder, Allergan, Amgen, Eli Lilly, Novartis and Teva, has no ownership interest and does not own stocks of any pharmaceutical company. MA serves as associate editor of Cephalalgia, associate editor of The Journal of Headache and Pain, and associate editor of Headache, and is the current president of the International Headache Society.
UR has acted as a consultant for Allergan, Amgen, Eli Lilly, Novartis, Teva, has served on advisory boards for Allergan, Amgen, Autonomic Technologies, Eli Lilly, Medscape, Novartis, Teva, and is a member of speakers’ bureaus for Allergan, Amgen, Eli Lilly, Medscape, Novartis, StreamedUp, Teva, and has received research support from the German Federal Ministry of Education and Research (BMBF) and Novartis. YH has served on advisory boards for Amgen, Novartis and Teva.
GB has received unrestricted grants, honoraria, personal fees, and travel grants from Allergan, Amgen, AstraZeneca, European Headache Foundation (EHF), Fresenius, Grünenthal, Janssen Cilag, Lilly, Linde AG, Menarini, Novartis, Österreichische Akademie der Wissenschaften (ÖAW), Österreichische Gesellschaft für Neurologie (ÖGN), Österreichische Kopfschmerzgesellschaft (ÖKSG), Pfizer, Reckitt Benkiser, St. Jude Medical, and Teva.
JHB has nothing to disclose.
HP is an employee of and stockholder in Amgen.
SC is an employee of and stockholder in Amgen.
DEC is an employee of and stockholder in Amgen.
FZ is an employee of and stockholder in Amgen.
JK is an employee of and stockholder in Novartis.
DDM is an employee of and stockholder in Amgen.
© 2021. The Author(s).
Figures
References
- Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47:355–363.
- Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38:1-211
- Schwedt TJ, Alam A, Reed ML, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018;19:38. doi: 10.1186/s10194-018-0865-z.
- Munksgaard SB, Madsen SK, Wienecke T (2019) Treatment of Medication Overuse Headache - a review. Acta Neurol Scand
- Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5:637. doi: 10.1186/s40064-016-2211-8.
- Porter JK, Di Tanna GL, Lipton RB, Sapra S, Villa G (2018) Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials. Pharmacoecon Open
- Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Headache. 2018;58:700–714. doi: 10.1111/head.13275.
- Messali A, Sanderson JC, Blumenfeld AM, et al. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey. Headache. 2016;56:306–322. doi: 10.1111/head.12755.
- Shi L, Lehto SG, Zhu DX, et al. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther. 2016;356:223–231. doi: 10.1124/jpet.115.227793.
- Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol. 2013;170:1293–1307. doi: 10.1111/bph.12129.
- Goadsby PJ, Reuter U, Hallstrom Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123–2132. doi: 10.1056/NEJMoa1705848.
- Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–434. doi: 10.1016/S1474-4422(17)30083-2.
- Tepper S et al (2018) Assessment of the Long-Term Safety and Efficacy of Erenumab During Open-Label Treatment of Subjects With Chronic Migraine. Data presented at 60th Annual Scientific Meeting of the American Headache Society, San Francisco
- Ashina M et al (2018) Long-term Safety and Tolerability of Erenumab: Three-plus Year Results from an Ongoing Open-Label Extension Study in Episodic Migraine. Data presented at 60th Annual Scientific Meeting of the American Headache Society, San Francisco
- Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology. 2017;89:1237–1243. doi: 10.1212/WNL.0000000000004391.
- Lipton RB, Tepper SJ, Silberstein SD, et al. Reversion From Chronic Migraine to Episodic Migraine Following Treatment With Erenumab: Results of a Post Hoc Analysis of a Randomized, 12-Week, Double-Blind Study and a 52-Week, Open-Label Extension. Cephalalgia. 2021;41:6–16. doi: 10.1177/0333102420973994.
- Goadsby PJ, Paemeleire K, Broessner G, et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;39:817–826. doi: 10.1177/0333102419835459.
- Ashina M, Stewart Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38:1611–1621. doi: 10.1177/0333102418788347.
- Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–1037. doi: 10.1177/0333102418759786.
- Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280–2287. doi: 10.1016/S0140-6736(18)32534-0.
- Sakai F, Takeshima T, Tatsuoka Y, et al. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. Headache. 2019;59:1731–1742. doi: 10.1111/head.13652.
- Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382–390. doi: 10.1016/S1474-4422(16)00019-3.
- Diener HC, Schorn CF, Bingel U, Dodick DW. The importance of placebo in headache research. Cephalalgia. 2008;28:1003–1011. doi: 10.1111/j.1468-2982.2008.01660.x.
- Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13:301–307. doi: 10.1007/s11916-009-0048-3.
- Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019;92:e2309–e2320. doi: 10.1212/WNL.0000000000007497.
- Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–936. doi: 10.1111/j.1526-4610.2010.01678.x.
- Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–814. doi: 10.1177/0333102410364677.
- Hines DM, Shah S, Multani JK, et al. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. Headache. 2021;61(4):590–602. doi: 10.1111/head.14068.
- Fang J, Korrer S, Johnson JC, et al. Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis. Adv Ther. 2021;38(6):2921–2934. doi: 10.1007/s12325-021-01677-y.
- Tepper SJ, Fang J, Vo P, et al. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. J Headache Pain. 2021;22(1):27. doi: 10.1186/s10194-021-01238-2.
- Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32. doi: 10.1186/s10194-020-01102-9.
- Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in Chronic Migraine: An Australian Experience. Headache 60(10):2555–2562
- Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence. J Headache Pain. 2020;3(1):84. doi: 10.1186/s10194-020-01151-0.
Source: PubMed